X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs SANOFI INDIA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD SANOFI INDIA LUPIN LTD/
SANOFI INDIA
 
P/E (TTM) x 27.0 39.0 69.3% View Chart
P/BV x 2.8 8.4 33.6% View Chart
Dividend Yield % 0.6 1.1 54.8%  

Financials

 LUPIN LTD   SANOFI INDIA
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
SANOFI INDIA
Dec-16
LUPIN LTD/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,4654,560 32.1%   
Low Rs7274,400 16.5%   
Sales per share (Unadj.) Rs349.61,028.5 34.0%  
Earnings per share (Unadj.) Rs5.6129.0 4.3%  
Cash flow per share (Unadj.) Rs29.6186.0 15.9%  
Dividends per share (Unadj.) Rs5.0068.00 7.4%  
Dividend yield (eoy) %0.51.5 30.1%  
Book value per share (Unadj.) Rs300.3753.6 39.9%  
Shares outstanding (eoy) m452.0823.03 1,963.0%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.14.4 72.0%   
Avg P/E ratio x197.234.7 567.7%  
P/CF ratio (eoy) x37.124.1 153.8%  
Price / Book Value ratio x3.65.9 61.4%  
Dividend payout %90.052.7 170.6%   
Avg Mkt Cap Rs m495,502103,174 480.3%   
No. of employees `00017.03.6 470.4%   
Total wages/salary Rs m28,6473,592 797.5%   
Avg. sales/employee Rs Th9,273.66,537.7 141.8%   
Avg. wages/employee Rs Th1,681.0991.4 169.5%   
Avg. net profit/employee Rs Th147.4819.8 18.0%   
INCOME DATA
Net Sales Rs m158,04223,686 667.2%  
Other income Rs m1,504708 212.4%   
Total revenues Rs m159,54524,394 654.0%   
Gross profit Rs m31,4755,281 596.0%  
Depreciation Rs m10,8591,313 827.0%   
Interest Rs m2,04415 13,623.3%   
Profit before tax Rs m20,0764,661 430.7%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,6440-   
Tax Rs m2,8851,691 170.6%   
Profit after tax Rs m2,5132,970 84.6%  
Gross profit margin %19.922.3 89.3%  
Effective tax rate %14.436.3 39.6%   
Net profit margin %1.612.5 12.7%  
BALANCE SHEET DATA
Current assets Rs m122,09515,673 779.0%   
Current liabilities Rs m50,9566,678 763.0%   
Net working cap to sales %45.038.0 118.5%  
Current ratio x2.42.3 102.1%  
Inventory Days Days8576 111.3%  
Debtors Days Days12022 537.4%  
Net fixed assets Rs m129,8768,098 1,603.8%   
Share capital Rs m904230 392.6%   
"Free" reserves Rs m134,86617,088 789.2%   
Net worth Rs m135,77117,356 782.3%   
Long term debt Rs m64,2450-   
Total assets Rs m263,05425,400 1,035.6%  
Interest coverage x10.8311.7 3.5%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.9 64.4%   
Return on assets %1.711.8 14.7%  
Return on equity %1.917.1 10.8%  
Return on capital %3.726.9 13.8%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m53,1417,145 743.8%   
Fx outflow Rs m19,3356,846 282.4%   
Net fx Rs m33,807299 11,306.6%   
CASH FLOW
From Operations Rs m17,5123,226 542.8%  
From Investments Rs m-14,073-1,555 905.0%  
From Financial Activity Rs m-14,921-1,818 820.7%  
Net Cashflow Rs m-11,482-147 7,810.7%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 60.4 0.3%  
Indian inst/Mut Fund % 11.3 14.4 78.5%  
FIIs % 31.9 14.6 218.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 10.5 96.2%  
Shareholders   98,259 15,184 647.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   MERCK LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  VENUS REMEDIES  CIPLA  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trims Losses; Rupee Devalues to Record Low(12:30 pm)

Stock markets in India trim losses to turn flat even as rupee fell 43 paise to hit record low of 70.29 against the US dollar.

Related Views on News

PFIZER at All Time High; BSE HEALTHCARE Index Up 0.9% (Market Updates)

Aug 16, 2018 | Updated on Aug 16, 2018

PFIZER share price has hit an all time high at Rs 3,056 (up 4.6%). The BSE HEALTHCARE Index is up by 0.9%. Among the top gainers in the BSE HEALTHCARE Index today are PFIZER (up 4.6%) and ABBOTT INDIA (up 0.2%). The top losers include NATCO PHARMA (down 0.1%) and CAPLIN POINT (down 0.1%).

PFIZER at All Time High; BSE HEALTHCARE Index Up 1.1% (Market Updates)

Aug 16, 2018 | Updated on Aug 16, 2018

PFIZER share price has hit an all time high at Rs 3,018 (up 4.0%). The BSE HEALTHCARE Index is up by 1.1%. Among the top gainers in the BSE HEALTHCARE Index today are PFIZER (up 4.0%) and SANOFI INDIA (up 0.8%). The top losers include ALKEM LABORATORIES (down 0.1%) and ABBOTT INDIA (down 0.2%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 16, 2018 03:07 PM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS